$Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.$

Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.

We performed post-marketing surveillance to evaluate the safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART). In total, 356 CART sessions in 147 patients at 22 centers were performed. The most common primary disease was cancer (128 cases, 300 sessions). Mean amount of...

Full description

Saved in:

Bibliographic Details
Main Authors:	Norio Hanafusa, Ayako Isoai, Tomoaki Ishihara, Tetsuya Inoue, Ken Ishitani, Taiju Utsugisawa, Toshihiko Yamaka, Tetsuya Ito, Hiroshi Sugiyama, Atsushi Arakawa, Yosuke Yamada, Yasuo Itano, Hirokazu Onodera, Ryosuke Kobayashi, Naoko Torii, Toyoko Numata, Taihei Kashiwabara, Yoshihiro Matsuno, Michio Kato
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0177303&type=printable
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.

Similar Items